Metoprolol Tartrate

Adults: Film-coated tablet Hypertension: The total daily dose of Metoprolol is 100 to 400 mg, given as a single dose or twice daily. The starting dose is 100 mg (two Metoprolol-50 tablets) per day. This may be increased by 100 mg per day at weekly intervals. If full control is not achieved with a single daily dose, a b.i.d. regimen should be started. Combination therapy with a diuretic or other antihypertensive agents may also be considered. Angina: Usually Metoprolol 50 mg (one Metoprolol-50 tablet) to 100 mg (two Metoprolol-50 tablets) twice or three times daily. Cardiac arrhythmias: Metoprolol 50 mg (one Metoprolol-50 tablet) b.i.d or t.i.d should usually control the condition. If necessary, the dose can be increased up to 300 mg per day in divided doses. After an acute arrhythmia has been treated with Metoprolol injection, continuation therapy with Metoprolol tablets should be started 4 to 6 hours later. The initial oral dose should not exceed 50 mg t.i.d. Hyperthyroidism: Metoprolol 50 mg (one Metoprolol-50 tablet) four times a day. The dose should be reduced once the euthyroid state is achieved. Myocardial infarction: Oral therapy should begin 15 minutes after the last injection, with 50 mg every 6 hours for 48 hours. Patients who cannot tolerate the full intravenous dose should be given half the suggested oral dose. For maintenance, the usual dose is 200 mg daily in divided doses. Elderly: There are no special dosage requirements in otherwise healthy elderly patients. Significant hepatic dysfunction: A reduction in dosage may be necessary. Extended-release tablet Hypertension: The usual initial dose is 25 to 100 mg daily as a single dose, whether used alone or added to a diuretic. Angina pectoris: The dose of extended-release Metoprolol Succinate should be individualized. The usual initial dose is 100 mg daily as a single dose. Heart failure: The recommended starting dose of sustained-release Metoprolol Succinate is 25 mg once daily for two weeks in patients with NYHA class II heart failure, and 12.5 mg once daily in patients with more severe heart failure. The dose may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. If treatment is to be stopped, the dose should be reduced gradually over 1 to 2 weeks. IV injection Arrhythmias: By intravenous injection, up to 5 mg at a rate of 1 to 2 mg/minute, repeated after 5 minutes if necessary, to a total dose of 10 to 15 mg. In surgery: By slow intravenous injection, 2 to 4 mg at induction or to control arrhythmias that develop during anaesthesia. Doses of 2 mg may be repeated to a maximum of 10 mg. Myocardial infarction: For early intervention within 12 hours of infarction, give 5 mg by intravenous injection every 2 minutes to a maximum of 15 mg. After 15 minutes, follow with 50 mg by mouth every 6 hours for 48 hours. Maintenance is 200 mg daily in divided doses.